WORK’s Hunan to proceed with the manufacturing of a new medical tech-based device

Announcement

WORK Medical Technology Group LTD, a well-known provider of medical devices in China, operates via its branch named Work (Hangzhou) Medical Treatment Equipment Co., Ltd and its other branches in China have announced an approval. An approval to its branch, Hunan Saitumofei Co., Ltd, to begin manufacturing from the Hunan Provincial Medical Products Administration for its robust Class 2 medical device named the ‘Artificial Intelligence (AI)-Automated Human Blood Cell Morphology Analyser’.

This ethical approval marks a significant milestone in the smart WORK Medical’s research and development strategy. This approval might also grant a position as the Company’s new AI-powered device as a major growth factor in the vat healthcare sector, according to its performance and value for healthcare.

About the Class 2 medical device

The new analyser (medical device) includes equipped analysis software and a fundamental unit. The main unit unifies a sample-handling, automatic oil-immersion unit, protective housing, control board, barcode scanner, and optical imaging system. It counts White blood cell differential on human blood smears and calculates morphological parameters of platelets and red blood cells. This helps clinicians in cell morphology screening.

The analyser is sponsored by modern AI automation and merges deep-learning algorithms, full-fledged automated workflow and high-speed digital imaging to address pre-classification. It also includes a full description, detailed information on the morphology of red blood cells, platelets in peripheral blood smears and white blood cells. The analyser will start manufacturing in the first half of 2026, engineered to improve consistency, precision, and efficiency in microscopic examinations. The new device also cuts operational costs and manual workload.

The Chief Executive Officer and Chairman of the Board of Directors of WORK Medical, Mr Shuang Wu, said, “This new analyser brings comprehensive AI technology into previous traditional medical testing to enhance consistency and meet efficiency and precision while reducing relevant costs and manual intervention. The device has successfully upgraded from auxiliary image-reading tool to a standardised, automated and remotely reachable intensive testing platform.”

“With the consistency in AI-pipeline integration and algorithm iteration, it might position itself as standard equipment in oncology and hematology departments at primary-care laboratories and tertiary hospitals. It's also focused on supporting a quality control enhancement, labor cost optimization and early screening of blood disorders. We are serious regarding this new product’s revenue capability and line growth for the Company.”